
```
Écrit par Pierre Fabre
```

Т

Mercredi, 26 Octobre 2016 14:51 - Mis à jour Mercredi, 26 Octobre 2016 14:55

```
Pierre Fabre
Boulder, Colo., and Castres, France (October 25, 2016) - Array BioPharma (NASDAQ: ARRY)
and Pierre Fabre
announced
today that
results from
the
Phase
3
COLUMBUS
trial of binimetinib and encorafenib
in
BRAF
mutant melanoma
will be presented
at
the 2016
Society for Melanoma Research (SMR)
Annual
Congress
in
Boston, Massachusetts
on November 9
Findings from
COLUMBUS evaluating the combination of encorafenib plus binimetinib
("combination
in patients with unresectable or metas
ta
tic
BRAF-
mutant melanoma will be presented as an oral
late-breaking abstract
```

## ARRAY BIOPHARMA AND PIERRE FABRE TO PRESENT PHASE 3 COLUMBUS TRIAL AT SOCIETY FOR N



Écrit par Pierre Fabre

mutant melanoma.

## **COLUMBUS TRIAL DATA**

Data from the Phase 3 study will be featured as an oral presentation during the late-breaking abstract session on Wednesday, November 9 from

10:00 - 1

0

15

M ET:

## ARRAY BIOPHARMA AND PIERRE FABRE TO PRESENT PHASE 3 COLUMBUS TRIAL AT SOCIETY FOR N

Écrit par Pierre Fabre Mercredi, 26 Octobre 2016 14:51 - Mis à jour Mercredi, 26 Octobre 2016 14:55

- Abstract 2617508: Results of COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

- Presenter: Keith T. Flaherty, M.D., Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and Professor of Medicine, Harvard Medical School, Boston, Massachusetts

As reported in late September, 577 patients were randomized 1:1:1 to receive the combination of encorafenib plus binimetinib, encorafenib alone, or vemurafenib alone.

In the analysis of the primary endpoint, the median PFS for patients treated with the combination of encorafenib plus binimetinib ("combination") was 14.9 months versus 7.3 months for patients treated with vemurafenib; HR (0.54), [95% CI 0.41-0.71], p